This trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
1 Primary · 15 Secondary · Reporting Duration: Up to 8 years
Experimental Treatment
Non-Treatment Group
1340 Total Participants · 4 Treatment Groups
Primary Treatment: Eflornithine plus sulindac · Has Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:North Carolina | 50.0% |
Minnesota | 50.0% |
18 - 65 | 100.0% |
Hennepin County Medical Center | 50.0% |
Southeastern Medical Oncology Center-Goldsboro | 50.0% |
Met criteria | 100.0% |
50.0% | |
Phone Call | 50.0% |